Overview

to Assess the Eradication Rate of 14-day Bismuth/Amoxicillin/PCAB Triple Therapy for the Treatment of Helicobacter Pylori Infection

Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of 14-day bismuth/amoxicillin/PCAB triple therapy for the treatment of Helicobacter pylori infection in Taiwan
Phase:
NA
Details
Lead Sponsor:
Kaohsiung Medical University
Collaborator:
An-Nan Hospital, China Medical University